Phio Pharmaceuticals announced its management will attend the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, to discuss its lead cancer treatment candidate PH-762 and strategic plans. PH-762 is an INTASYL siRNA compound aimed at treating skin cancers by silencing the PD-1 gene, offering a potential non-surgical option. The company plans to update investors on clinical progress and upcoming initiatives to advance PH-762's development and value creation. This event provides insight into Phio's efforts to enhance immune response against cancer using its proprietary gene-silencing technology.
Senteon was awarded the Best Solution Patch and Configuration Management at the 2026 Top InfoSec Innovator Awards by Cyber Defense Magazine. The company’s platform automates endpoint hardening and continuously monitors security configurations to redu...
RENK Group AG has sold its slide bearings business to Austrian company Miba AG to sharpen its focus on the defense sector, aiming to increase defense-related revenue to 90% by 2030. The sale does not affect RENK's Marine & Industry civilian business,...
RENK Group AG is selling its slide bearings business to Austrian company Miba AG as part of a strategic shift to focus more on its defense sector. The sale supports RENK's plan to increase defense-related revenue to about 90% by 2030, while the civil...
RENK Group AG, through its subsidiary RENK GmbH, has signed a binding agreement to sell its Slide Bearings business to Austria's Miba AG. The Slide Bearings segment produces standardized bearings used mainly in industrial and civil markets. This sale...
RENK Group AG, through its subsidiary RENK GmbH, has signed a binding agreement to sell its Slide Bearings business to Austria's Miba AG. This unit produces slide bearings mainly used in industrial and civilian markets. The sale aligns with RENK's 20...
